KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Current Deferred Revenue (2016 - 2017)

Historic Current Deferred Revenue for Supernus Pharmaceuticals (SUPN) over the last 7 years, with Q4 2017 value amounting to $287000.0.

  • Supernus Pharmaceuticals' Current Deferred Revenue rose 3732.06% to $287000.0 in Q4 2017 from the same period last year, while for Dec 2017 it was $287000.0, marking a year-over-year increase of 3732.06%. This contributed to the annual value of $287000.0 for FY2017, which is 3732.06% up from last year.
  • According to the latest figures from Q4 2017, Supernus Pharmaceuticals' Current Deferred Revenue is $287000.0, which was up 3732.06% from $287000.0 recorded in Q3 2017.
  • In the past 5 years, Supernus Pharmaceuticals' Current Deferred Revenue ranged from a high of $417000.0 in Q1 2013 and a low of $143000.0 during Q2 2014
  • Moreover, its 5-year median value for Current Deferred Revenue was $207500.0 (2016), whereas its average is $218350.0.
  • Over the last 5 years, Supernus Pharmaceuticals' Current Deferred Revenue had its largest YoY gain of 7974.14% in 2013, and its largest YoY loss of 5984.25% in 2013.
  • Quarter analysis of 5 years shows Supernus Pharmaceuticals' Current Deferred Revenue stood at $204000.0 in 2013, then dropped by 29.9% to $143000.0 in 2014, then rose by 23.08% to $176000.0 in 2015, then increased by 18.75% to $209000.0 in 2016, then soared by 37.32% to $287000.0 in 2017.
  • Its Current Deferred Revenue was $287000.0 in Q4 2017, compared to $287000.0 in Q3 2017 and $287000.0 in Q2 2017.